4-(p-(carboxyphenyl)amino)pyridine | 80028-43-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(p-(carboxyphenyl)amino)pyridine
• 英文别名: 4-(pyridin-4-ylamino)benzoic acid；4-[4]pyridylamino-benzoic acid；4-[4]Pyridylamino-benzoesaeure；4-(4-pyridinylamino)benzoic acid
• CAS: 80028-43-9
• 化学式: C₁₂H₁₀N₂O₂
• 分子量: 214.224
• InChiKey: OEWZQATXQINCCC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.52
• 重原子数：
  16.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  62.22
• 氢给体数：
  2.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  4-(p-(carboxyphenyl)amino)pyridine 在 氯化亚砜 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 20.33h， 生成 1-methyl-4-{4-[(4-nitroanilino)carbonyl]anilino}pyridinium chloride
  参考文献：
  名称：

  Structure–activity relationships for 4-anilinoquinoline derivatives as inhibitors of the DNA methyltransferase enzyme DNMT1

  摘要：

  A series of 4-anilinoquinoline derivatives related to the known inhibitor SGI-1027, containing side chains of varying pK(a), were prepared by acid-catalysed coupling of the pre-formed side chains with 4-chloroquinolines. The compounds were evaluated for their ability to reduce the level of DNMT1 protein in HCT116 human colon carcinoma cells by Western blotting. With a very strongly basic N-methylpyridinium side chain, only NHCO-linked compounds were effective, whereas less strongly basic ((diaminomethylene) hydrazono)ethyl or 3-methylpyrimidine-2,4-diamine side chains allowed both NHCO- and CONH-linked compounds to show activity. In contrast, the pK(a) of the quinoline unit had little apparent influence on activity. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.03.033
• 作为产物：
  描述：

  methyl 4-(pyridin-4-ylamino)benzoate 在 水 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以90%的产率得到4-(p-(carboxyphenyl)amino)pyridine
  参考文献：
  名称：

  [EN] AKT3 MODULATORS
  [FR] MODULATEURS D'AKT3

  摘要：

  公式Ia、Ib或Ic的化合物被描述，其中各种取代基在此处被定义。这些化合物可以在体外或体内调节Akt3的性质或效应，并且也可以单独或与其他药剂结合在预防或治疗各种疾病方面使用。描述了合成这些化合物的方法。还描述了使用这些化合物或组合物的药物组合物和使用这些化合物或组合物，单独或与其他药剂或组合物结合在预防或治疗各种疾病方面的方法。

  公开号：

  WO2021226517A1

文献信息

• [EN] AKT3 MODULATORS<br/>[FR] MODULATEURS DE AKT3
  申请人：GEORGIAMUNE LLC

  公开号：WO2021226519A1

  公开（公告）日：2021-11-11

  Compounds of Formula la, lb, or Ic, are described, where the various substituents are defined herein. The compounds can modulate a property or effect of Akt3 in vitro or in vivo, and can also be used, individually or in combination with other agents, in the prevention or treatment of a variety of conditions. Methods for synthesizing the compounds are described. Pharmaceutical compositions and methods of using these compounds or compositions, individually or in combination with other agents or compositions, in the prevention or treatment of a variety of conditions are also described.

  公式Ia、Ib或Ic的化合物已被描述，其中各种取代基在此定义。这些化合物可以在体外或体内调节Akt3的性质或效果，并且也可以单独或与其他药剂结合在预防或治疗各种疾病方面使用。描述了合成这些化合物的方法。还描述了制药组合物以及使用这些化合物或组合物在预防或治疗各种疾病中单独或与其他药剂或组合物结合的方法。
• Substituted aniline derivatives useful as histamine H3 antagonists
  申请人：Solomon M. Daniel

  公开号：US20070142394A1

  公开（公告）日：2007-06-21

  Disclosed are compounds of the formula or a pharmaceutically acceptable salt thereof, wherein M 1 is M 2 is N; X is a bond, optionally substituted alkylene, alkenylene, —O—, —CH 2 N(R 12 )—, —N(R 12 )CH 2 —, —N(R 12 )—, —NHC(O)—, —OCH 2 —, —CH 2 O—, or —S(O) 0-2 —; and Y is —(CH 2 ) 1-2 —, —C(═O)—, —C(═NOR 13 )— or —SO 0-2 —; or M 1 is N; M 2 is N or CH; X is a bond, alkylene, alkenylene, —C(O)—, —NHC(O)—, —OC(O)— or —S(O) 1-2 —; Y is —(CH 2 ) 1-2 —, —C(═O)— or —SO 0-2 —; and when M 2 is CH, Y is also Y is —O— or —C(═NOR 13 )—; Z is a bond or optionally substituted alkylene or alkenylene; U and W are CH, or one is CH and one is N; R 1 is optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl; R 2 is optionally substituted alkyl, alkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; and compositions and methods of treating obesity, metabolic syndrome and a cognition deficit disorder, alone or in combination with other agents.

  揭示了以下化合物的结构式或其药学上可接受的盐，其中M1为M2为N；X为键合，可选择地取代的烷基，烯基，—O—，—CH2N(R12)—，—N(R12)CH2—，—N(R12)—，—NHC(O)—，—OCH2—，—CH2O—或—S(O)0-2—；Y为—(CH2)1-2—，—C(═O)—，—C(═NOR13)—或—SO0-2—；或者M1为N；M2为N或CH；X为键合，烷基，烯基，—C(O)—，—NHC(O)—，—OC(O)—或—S(O)1-2—；Y为—(CH2)1-2—，—C(═O)—或—SO0-2—；当M2为CH时，Y也为—O—或—C(═NOR13)—；Z为键合或可选择地取代的烷基或烯基；U和W为CH，或其中一个为CH，另一个为N；R1为可选择地取代的烷基，环烷基，芳基，芳基烷基，杂环芳基，杂环烷基；R2为可选择地取代的烷基，烯基，芳基，芳基烷基，杂环芳基，杂环芳基烷基，环烷基或杂环烷基；其余变量如规范中定义；以及治疗肥胖症、代谢综合征和认知缺陷障碍的组合物和方法，可单独使用或与其他药物组合使用。
• Antihypertensive pyridylaminobenzamide compounds
  申请人：Sterling Drug Inc.

  公开号：US04610991A1

  公开（公告）日：1986-09-09

  A series of 4-pyridinylaminobenzamides, useful as antihypertensive agents, was prepared from the corresponding 4-pyridinylaminobenzoic acids by reacting the acid chloride of the latter with ammonia or a primary or secondary amine. Alternatively the compounds were prepared by reacting an aminobenzamide with 4-chloropyridine or equivalent reagent.

  一系列4-吡啶基氨基苯甲酰胺，可用作降压药物，是通过将相应的4-吡啶基氨基苯甲酸与氨或一级或二级胺的酸氯化物反应制备而成的。另外，这些化合物也可以通过将氨基苯甲酰胺与4-氯吡啶或等效试剂反应制备而成。
• [EN] NOVEL AMINOMETHYL-PHENOL DERIVATIVES AS ANTIMALARIAL AGENTS<br/>[FR] NOUVEAUX DÉRIVÉS D'AMINOMÉTHYLPHÉNOL EN TANT QU'AGENTS ANTIPALUDIQUES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2014072903A1

  公开（公告）日：2014-05-15

  The invention relates to novel aminomethyl-phenol derivatives of formula I wherein R1 to R4, X, A and B are as defined for formula I and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including pharmaceutical compositions containing one or more of those compounds and their use as medicaments for the treatment or prevention of protozoal infections, such as especially malaria.

  该发明涉及一种新的氨甲基酚衍生物，其化学式为I，其中R1至R4、X、A和B如化学式I所定义，并且其作为药物成分用于制备药物组合物。该发明还涉及相关方面，包括含有其中一种或多种化合物的药物组合物以及其作为药物治疗或预防原虫感染，尤其是疟疾的用途。
• QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION
  申请人：Phiasivongsa Pasit

  公开号：US20090285772A1

  公开（公告）日：2009-11-19

  Quinoline derivatives, particularly 4-anilinoquinoline derivatives, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation are provided. Also provided are methods for formulating and administering these compounds or compositions to treat conditions such as cancer and hematological disorders.

  提供了喹啉衍生物，特别是4-苯胺基喹啉衍生物。这样的喹啉衍生物可用于调节DNA甲基化，例如通过选择性抑制DNA甲基转移酶DNMT1，有效抑制C-5位置的胞嘧啶甲基化。提供了合成多种4-苯胺基喹啉衍生物和调节DNA甲基化的方法。还提供了制剂和给药这些化合物或组合物以治疗癌症和血液疾病的方法。